L
Liquidia Corporation (LQDA)
NCM – Real Time Price. Currency in USD
56.60
+3.47 (6.53%)
At close: May 12, 2026, 4:00 PM EDT
56.75
+0.15 (0.27%)
Pre-market: May 13, 2026, 5:34 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
56.60
+3.47 (6.53%)
At close: May 12, 2026, 4:00 PM EDT
56.75
+0.15 (0.27%)
Pre-market: May 13, 2026, 5:34 AM EDT
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
| Name | Position |
|---|---|
| Dr. Rajeev Saggar M.D. | Chief Medical Officer |
| Dr. Roger A. Jeffs Ph.D. | CEO & Director |
| Matt Snow | Senior Vice President of Sales |
| Mr. Christian Perez Font | Senior VP, Chief Compliance Officer & Associate General Counsel |
| Mr. Michael Kaseta | COO & CFO |
| Mr. Michael Post | Senior Vice President of Marketing |
| Mr. Russell Schundler | General Counsel & Corporate Secretary |
| Mr. Scott Moomaw | Chief Commercial Officer |
| Ms. Dana Boyle | Chief Accounting Officer |
| Ms. Sarah Krepp SPHR | Chief Human Resources Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-11 | 8-K | tm2614109d1_8k.htm |
| 2026-05-11 | 10-Q | lqda-20260331x10q.htm |
| 2026-04-24 | DEFA14A | tm261471d3_defa14a.htm |
| 2026-04-24 | DEF 14A | tm261471-1_def14a.htm |
| 2026-03-05 | S-3ASR | tm267588-1_s3asr.htm |
| 2026-01-09 | 8-K | tm262716d1_8k.htm |
| 2025-11-03 | 8-K | tm2530004d1_8k.htm |
| 2025-10-30 | 8-K | tm2529678d1_8k.htm |
| 2025-08-12 | 10-Q | lqda-20250630x10q.htm |
| 2025-07-01 | 8-K | tm2519480d1_8k.htm |